Myriad jumps after saying it will present four new studies at ASHG
Earlier today, Myriad Genetics announced it will present four new studies at the American Society of Human Genetics Annual Meeting being held Oct. 18-22 in Vancouver, British Columbia. The research being presented highlights the clinical utility of Myriad's myVision Variant Classification Program and myRisk Hereditary Cancer gene panel test. "Precision medicine is dependent on the accuracy of the information being provided to patients, and Myriad's myVision is the most advanced variant classification program available to determine whether a patient's genetic mutation is benign or deleterious," said Johnathan Lancaster, M.D., Ph.D, chief medical officer, Myriad Genetic Laboratories. "At ASHG, we are excited to present four new studies, which advance the state of the art of genetic testing and meet the scientific needs of researchers and clinicians." shares of Myriad Genetics are up 87c or 4.65% to $19.50 per share.